Rafael Holdings Phase 3 NPC drug trial misses primary endpoint
Tweet Send to a Friend
Rafael Holdings, Inc. (NYSE: RFL) announced topline results from its pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ in 94 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


